查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2086056

偏頭痛治療市場：2026-2032年全球市場預測（依藥物類別、類型、適應症、患者年齡層、最終用戶和通路分類）

Migraine Drugs Market by Drug Class, Types, Indication, Patient Age Group, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，偏頭痛治療市場將成長至 100.1 億美元，複合年成長率為 8.93%。

主要市場統計數據
基準年 2025 55億美元
預計年份：2026年 59.8億美元
預測年份 2032 100.1億美元
複合年成長率 (%) 8.93%

偏頭痛治療市場執行摘要

由於偏頭痛的高發病率、對日常生活的嚴重干擾、反覆發作以及常常缺乏適當的治療，它是神經病學領域臨床最活躍的疾病之一。全球疾病負擔調查始終將偏頭痛列為全球導致失能調整後存活年（DALYs）的主要原因之一，尤其是在勞動年齡成人和女性中。因此，在基層醫療、神經病學、零售藥房和數位醫療管道中，對急性偏頭痛治療、偏頭痛預防以及對患者的正確識別都存在持續的需求。

偏頭痛治療前景的變革性變化

偏頭痛藥物領域最顯著的轉變是從廣泛的症狀管理轉向基於機制的偏頭痛治療。 CGRP標靶藥物能夠支持偏頭痛獨特的生物機制，用於急性期治療和預防性治療。同時，吉泮類藥物為無法使用或對曲坦類藥物無反應的患者提供了一種具有臨床意義的非血管收縮性治療選擇。這改變了處方途徑、競爭格局和患者的預期。

人工智慧對偏頭痛藥物的累積影響

人工智慧 (AI) 正逐漸成為偏頭痛治療各領域的累積驅動力，從藥物發現和臨床開發到診斷支援和治療最佳化，無一例外。在研發階段，AI 驅動的分析能夠識別分子標靶、分析基因組學和蛋白​​質組學數據，並透過最佳化納入標準、選擇對照組和提高終點指標的敏感性來改善臨床試驗方案設計。在開發專案中，機器學習能夠支援臨床實驗的選擇、受試者的招募、安全性訊號的檢測，並利用保險理賠資料、電子健康記錄和病患報告結局 (PRO) 產生真實世界證據。

關於偏頭痛藥物引入的關鍵區域性見解

北美仍是偏頭痛藥物領域極具影響力的地區。這是因為美國是CGRP單株抗體、吉泮類藥物和新型急性治療藥物的早期應用市場，這得益於其大規模的專科醫生群體、廣泛的臨床研究活動以及成熟的藥房報銷體系。在加拿大，採用實證醫學報銷流程，雖然減緩了藥物的普及速度，但也加強了對藥物價值的審查。在全部區域，准入管理、共同支付機制、預核准和階梯療法規則共同影響著急性偏頭痛治療和預防性療法的實際可及性。

制定偏頭痛市場策略計畫的關鍵群體洞察

在東協地區，都市化、私人醫療體系的擴張、數位醫療工具的廣泛應用以及人們對神經系統疾病認知的提高，都推動了偏頭痛藥物的需求成長，但各成員國獲得專科醫生主導的預防性醫療服務的機會仍然不均衡。儘管海灣合作理事會（GCC）成員國受益於大量的醫療投資、完善的醫院基礎設施以及創新藥物的廣泛應用，但報銷政策、國家採購重點以及專科醫生的處方流程等因素，仍然影響著患者獲得治療的速度。

來自偏頭痛治療市場主要國家的洞察

美國在全球創新偏頭痛治療藥物的商業化方面處於領先地位，CGRP抑制劑、吉泮類藥物、地坦類藥物以及用於治療慢性偏頭痛的A型肉毒桿菌毒素等藥物已廣泛應用，並透過專業藥房建立了完善的處方管道。然而，支付方的監管規定對處方和持續用藥有顯著影響。加拿大強調臨床價值和報銷審查，而墨西哥和巴西是拉丁美洲的重要市場，在這些國家，獲得專科醫生診療、私人保險覆蓋、公共採購以及已上市的曲坦類藥物和學名藥的供應情況決定了這些藥物的廣泛應用。在歐洲，英國、德國、法國、義大利和西班牙的神經系統醫療保健體系較為完善，但國家醫療技術評估、地區處方規則和報銷標準會影響病患的用藥。俄羅斯擁有大量偏頭痛患者，但面臨特定市場監管、供應和用藥的限制。

為偏頭痛治療行業的領導者提供的實用建議

產業領導企業應優先考慮差異化的臨床定位，而非僅競相進入特定藥物類別。對於急性偏頭痛藥物，需要提供關於起效速度、緩解持續性疼痛、減輕最棘手症狀、功能恢復、耐受性以及是否適用於具有心血管風險因素患者的證據。對於預防性療法，需要提供證據證明其能夠持續減少每月偏頭痛發作天數、改善生活品質、降低停藥率，並提供符合患者偏好的實用給藥方法。

偏頭痛治療市場洞察調查方法

本執行摘要基於三角測量法的研究途徑，該方法結合了公開的監管資訊、臨床指南趨勢、經同行評審的偏頭痛疾病負擔證據、產品類別分析以及市場進入觀察。疾病負擔的核心背景與全球疾病負擔研究和世界衛生組織（WHO）頭痛疾病公共衛生框架等資訊來源一致，而對治療格局的洞察則反映了已通過核准的藥物類別、循證治療路徑和已確立的臨床應用模式。調查方法強調透過交叉引用流行病學、法規核准、治療機制、指南建議、保險報銷趨勢和當地醫療保健基礎設施檢驗數據。結論：偏頭痛治療創新的未來

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：偏頭痛治療市場：依藥物類別分類

  • CGRP單株抗體
    • 艾普汀珠單抗
    • 依瑞奈單抗
    • 弗雷馬內珠單抗
    • 加爾卡內茲馬
  • 距離
  • 麥角衍生物
    • Dihydroergotamine
    • 麥角胺
  • 吉潘特系統
    • 阿特格潘斯
    • 霜化劑
    • Hublot Gepanto
  • NSAID
    • 雙氯芬酸鈉
    • Ibuprofen
    • 萘普生
  • 曲坦類藥物
    • 阿爾莫托利普坦
    • 依來曲坦
    • 氟巴曲坦
    • 那拉曲坦
    • Rizatriptan
    • Sumatriptan
    • 佐米曲坦

第8章：偏頭痛治療市場：依類型分類

  • 注射藥物
    • 靜脈
    • 皮下
  • 鼻噴劑
  • 口服
    • 膠囊
    • 藥片
  • 外用

第9章：偏頭痛治療市場：依適應症分類

  • 急性治療
  • 預防性治療

第10章：偏頭痛治療市場：依患者年齡層別分類

  • 成人
  • 兒童

第11章 偏頭痛治療市場：依最終用戶分類

  • 醫院和診所
  • 居家醫療
  • 專業醫療中心

第12章：偏頭痛治療市場：依通路分類

  • 離線
  • 線上

第13章：偏頭痛治療市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章 偏頭痛治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 偏頭痛治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • AbbVie Inc.
  • Almirall SA
  • Amgen Inc.
  • Apotex Inc.
  • AstraZeneca plc
  • Aurobindo Pharma Limited
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • Esteve Pharmaceuticals SA
  • Ferrer Internacional SA
  • GlaxoSmithKline plc
  • Grunenthal GmbH
  • Hikma Pharmaceuticals PLC
  • Ipsen SA
  • Johnson & Johnson
  • Lundbeck A/S
  • Lupin Limited
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Viatris Inc.
  • Zydus Lifesciences Limited
Product Code: MRR-036C5CF3A820

The Migraine Drugs Market is projected to grow by USD 10.01 billion at a CAGR of 8.93% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.50 billion
Estimated Year [2026] USD 5.98 billion
Forecast Year [2032] USD 10.01 billion
CAGR (%) 8.93%

Migraine Drugs Market Executive Summary

Migraine drugs occupy one of the most clinically active areas of neurology because migraine is common, disabling, recurrent, and often undertreated. The Global Burden of Disease study has consistently ranked migraine among the leading causes of years lived with disability worldwide, and migraine is especially burdensome among working-age adults and women. This creates durable need for acute migraine treatments, preventive migraine therapies, and better patient identification across primary care, neurology, retail pharmacy, and digital health channels.

The landscape has moved beyond historical reliance on nonsteroidal anti-inflammatory drugs, triptans, ergots, antiemetics, and off-label preventive medicines. Calcitonin gene-related peptide (CGRP) monoclonal antibodies, oral gepants, nasal gepants, ditans, and onabotulinumtoxinA for chronic migraine have expanded the migraine drug landscape with more mechanism-based options. For life sciences leaders, payer organizations, and care delivery networks, the strategic priority is no longer only product availability; it is matching the right migraine medicine to the right patient at the right point in the treatment journey.

Transformative Shifts in the Migraine Treatment Landscape

The most important shift in the migraine drugs landscape is the transition from broad symptom control to mechanism-led migraine therapy. CGRP-targeted medicines have validated migraine-specific biology in both acute and preventive care, while gepants have added non-vasoconstrictive options that may be clinically relevant for patients who cannot use or do not respond to triptans. This has changed prescribing pathways, competitive positioning, and patient expectations.

A second shift is the movement toward patient-centered treatment endpoints. Reduction in monthly migraine days remains a key clinical measure, but stakeholders increasingly evaluate onset of relief, freedom from the most bothersome symptom, tolerability, medication-overuse risk, adherence, and functional recovery. As more therapies compete within acute and preventive segments, real-world evidence, formulary access, prior authorization design, and persistence data are becoming as influential as pivotal trial efficacy.

Cumulative Impact of Artificial Intelligence on Migraine Drugs

Artificial intelligence is becoming a cumulative enabler across migraine drug discovery, clinical development, diagnosis support, and treatment optimization. In research, AI-enabled analytics can help identify molecular targets, analyze genomics and proteomics data, and improve trial protocol design by refining eligibility criteria, comparator selection, and endpoint sensitivity. In development programs, machine learning can support site selection, patient recruitment, safety signal detection, and real-world evidence generation from claims, electronic health records, and patient-reported outcomes.

In care delivery, AI has practical value when it improves migraine characterization without replacing clinical judgment. Digital headache diaries, wearable data, and natural-language processing of clinical notes can help detect attack patterns, triggers, medication use, and response to therapy. The near-term opportunity is decision support that helps clinicians distinguish episodic migraine, chronic migraine, medication-overuse headache, and comorbid conditions while aligning treatment with evidence-based guidelines, patient preferences, and payer requirements.

Key Regional Insights Across Migraine Drug Adoption

North America remains a highly influential region for migraine drugs because the United States has been an early launch environment for CGRP monoclonal antibodies, gepants, and newer acute therapies, supported by a large specialist base, extensive clinical research activity, and mature pharmacy benefit infrastructure. Canada follows evidence-based reimbursement pathways that can moderate uptake but strengthen value scrutiny. Across the region, access management, copay design, prior authorization, and step-therapy rules shape real-world utilization of acute migraine treatment and preventive migraine therapy.

Europe combines strong neurology expertise with centralized and country-specific health technology assessment, making comparative value, clinical benefit, and cost-effectiveness central to adoption. The European Union emphasizes regulatory consistency, evidence generation, pharmacovigilance, and post-authorization monitoring, while the United Kingdom, Germany, France, Italy, and Spain apply distinct reimbursement and prescribing controls. Asia-Pacific is expanding as Japan, China, South Korea, Australia, India, and ASEAN countries improve diagnosis, physician education, and access to migraine therapeutics, although affordability and specialist availability vary widely across urban and rural settings. Latin America, the Middle East, and Africa show meaningful unmet need, with adoption linked to private healthcare expansion, public reimbursement evolution, hospital formulary inclusion, physician education, and broader availability of branded and generic migraine medicines.

Key Group Insights for Strategic Migraine Market Planning

Within ASEAN, migraine drug demand is shaped by urbanization, expanding private healthcare capacity, increasing use of digital health tools, and wider recognition of neurological disorders, but access to specialist-led preventive care remains uneven across member countries. The GCC benefits from high healthcare investment, strong hospital infrastructure, and rising adoption of innovative medicines, while reimbursement policy, national procurement priorities, and specialty prescribing pathways influence speed of patient access.

The European Union is a pivotal group for migraine drugs because harmonized regulatory standards coexist with country-level reimbursement decisions and health technology assessment processes. BRICS markets combine large patient populations with different levels of affordability, local manufacturing capacity, clinical guideline adoption, and formulary inclusion, creating both scale and access challenges. G7 countries concentrate much of the clinical research, branded therapy uptake, payer evidence generation, and guideline influence for migraine therapeutics. NATO members overlap substantially with advanced North American and European markets, where supply chain resilience, regulatory alignment, pharmacovigilance systems, and health system capacity support more consistent availability of migraine drugs.

Key Country Insights in the Migraine Drugs Market

The United States leads global commercialization of innovative migraine drugs, with broad availability of CGRP inhibitors, gepants, ditans, onabotulinumtoxinA for chronic migraine, and specialty pharmacy pathways, but payer controls strongly affect prescribing and persistence. Canada emphasizes clinical value and reimbursement review, while Mexico and Brazil represent important Latin American markets where specialist access, private insurance coverage, public procurement, and availability of established triptans and generics determine uptake. In Europe, the United Kingdom, Germany, France, Italy, and Spain each maintain strong neurology systems, but national health technology assessment, regional prescribing rules, and reimbursement criteria shape patient access; Russia has a sizeable migraine population but faces market-specific regulatory, supply, and access constraints.

In Asia-Pacific, China and India offer scale but require affordability strategies, physician education, primary care diagnosis, and wider availability of evidence-based acute and preventive migraine treatments. Japan has high clinical sophistication and an aging population that elevates the need for well-tolerated therapies with clear safety profiles. Australia supports evidence-based access through national reimbursement systems, while South Korea combines advanced healthcare infrastructure with increasing adoption of innovative neurology medicines. Across all countries, the central challenge is converting migraine prevalence into diagnosed, appropriately treated, adherent, and outcomes-monitored patient populations.

Actionable Recommendations for Migraine Drug Industry Leaders

Industry leaders should prioritize differentiated clinical positioning rather than compete only on class participation. Acute migraine therapies need evidence on speed of onset, sustained pain freedom, relief from the most bothersome symptom, functional recovery, tolerability, and suitability for patients with cardiovascular risk factors. Preventive therapies should demonstrate durable reductions in monthly migraine days, improved quality of life, low discontinuation, and practical administration options that fit patient preferences.

Commercial teams should integrate market access evidence early, including real-world adherence, emergency department avoidance, workplace productivity, reduction in medication overuse, and patient-reported outcomes. Medical affairs organizations can create value by supporting clinician education on migraine diagnosis, chronic migraine identification, medication-overuse headache, comorbid depression and anxiety, and rational sequencing of triptans, gepants, ditans, CGRP monoclonal antibodies, and botulinum toxin. Partnerships with digital headache platforms, specialty pharmacies, and patient support programs can strengthen adherence while improving outcomes documentation.

Research Methodology for Migraine Drugs Market Insights

This executive summary is built from a triangulated research approach using publicly available regulatory information, clinical guideline trends, peer-reviewed migraine burden evidence, product class analysis, and market access observations. Core disease-burden context is aligned with sources such as the Global Burden of Disease study and the World Health Organization's public health framing of headache disorders, while therapy landscape insights reflect approved drug classes, evidence-based treatment pathways, and established clinical use patterns. The methodology emphasizes data validation through cross-checking of epidemiology, regulatory approvals, therapeutic mechanisms, guideline recommendations, reimbursement dynamics, and regional healthcare infrastructure. Conclusion: The Future of Migraine Drug Innovation

The migraine drugs market is entering a more sophisticated phase defined by targeted mechanisms, patient segmentation, payer evidence requirements, and digital support. High disease burden, persistent underdiagnosis, variable treatment access, and the need for better acute and preventive outcomes sustain demand across developed and emerging healthcare systems.

Future leadership will depend on evidence quality, access strategy, treatment personalization, and the ability to demonstrate measurable value beyond symptom reduction. Organizations that combine innovative migraine therapeutics with real-world data, physician education, equitable access planning, and patient support will be best positioned to improve outcomes and strengthen long-term relevance.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Migraine Drugs Market, by Drug Class

  • 7.1. CGRP Monoclonal Antibodies
    • 7.1.1. Eptinezumab
    • 7.1.2. Erenumab
    • 7.1.3. Fremanezumab
    • 7.1.4. Galcanezumab
  • 7.2. Ditans
  • 7.3. Ergot Derivatives
    • 7.3.1. Dihydroergotamine
    • 7.3.2. Ergotamine
  • 7.4. Gepants
    • 7.4.1. Atogepant
    • 7.4.2. Rimegepant
    • 7.4.3. Ubrogepant
  • 7.5. NSAID
    • 7.5.1. Diclofenac
    • 7.5.2. Ibuprofen
    • 7.5.3. Naproxen
  • 7.6. Triptans
    • 7.6.1. Almotriptan
    • 7.6.2. Eletriptan
    • 7.6.3. Frovatriptan
    • 7.6.4. Naratriptan
    • 7.6.5. Rizatriptan
    • 7.6.6. Sumatriptan
    • 7.6.7. Zolmitriptan

8. Migraine Drugs Market, by Types

  • 8.1. Injectable
    • 8.1.1. Intravenous
    • 8.1.2. Subcutaneous
  • 8.2. Nasal
  • 8.3. Oral
    • 8.3.1. Capsule
    • 8.3.2. Tablet
  • 8.4. Topical

9. Migraine Drugs Market, by Indication

  • 9.1. Acute Treatment
  • 9.2. Preventive Treatment

10. Migraine Drugs Market, by Patient Age Group

  • 10.1. Adult
  • 10.2. Pediatric

11. Migraine Drugs Market, by End User

  • 11.1. Hospitals & Clinics
  • 11.2. Home Care Settings
  • 11.3. Specialty Centers

12. Migraine Drugs Market, by Distribution Channel

  • 12.1. Offline
  • 12.2. Online

13. Migraine Drugs Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Migraine Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Migraine Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. AbbVie Inc.
  • 17.2. Almirall S.A.
  • 17.3. Amgen Inc.
  • 17.4. Apotex Inc.
  • 17.5. AstraZeneca plc
  • 17.6. Aurobindo Pharma Limited
  • 17.7. Bayer AG
  • 17.8. Bristol-Myers Squibb Company
  • 17.9. Cipla Limited
  • 17.10. Dr. Reddy's Laboratories Ltd.
  • 17.11. Eli Lilly and Company
  • 17.12. Esteve Pharmaceuticals S.A.
  • 17.13. Ferrer Internacional S.A.
  • 17.14. GlaxoSmithKline plc
  • 17.15. Grunenthal GmbH
  • 17.16. Hikma Pharmaceuticals PLC
  • 17.17. Ipsen S.A.
  • 17.18. Johnson & Johnson
  • 17.19. Lundbeck A/S
  • 17.20. Lupin Limited
  • 17.21. Merck & Co., Inc.
  • 17.22. Novartis AG
  • 17.23. Pfizer Inc.
  • 17.24. Sanofi S.A.
  • 17.25. Sun Pharmaceutical Industries Ltd.
  • 17.26. Teva Pharmaceutical Industries Ltd.
  • 17.27. Torrent Pharmaceuticals Ltd.
  • 17.28. Viatris Inc.
  • 17.29. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL MIGRAINE DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL MIGRAINE DRUGS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL MIGRAINE DRUGS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL MIGRAINE DRUGS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL MIGRAINE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL MIGRAINE DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL MIGRAINE DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TYPES, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TYPES, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL MIGRAINE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CGRP MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CGRP MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CGRP MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL EPTINEZUMAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL EPTINEZUMAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL EPTINEZUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ERENUMAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ERENUMAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ERENUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL FREMANEZUMAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL FREMANEZUMAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL FREMANEZUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GALCANEZUMAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GALCANEZUMAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GALCANEZUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DITANS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DITANS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DITANS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ERGOT DERIVATIVES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ERGOT DERIVATIVES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ERGOT DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DIHYDROERGOTAMINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DIHYDROERGOTAMINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DIHYDROERGOTAMINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ERGOTAMINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ERGOTAMINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ERGOTAMINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GEPANTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GEPANTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GEPANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ATOGEPANT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ATOGEPANT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ATOGEPANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL RIMEGEPANT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL RIMEGEPANT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL RIMEGEPANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL UBROGEPANT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL UBROGEPANT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL UBROGEPANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NSAID MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NSAID MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NSAID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DICLOFENAC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DICLOFENAC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DICLOFENAC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL IBUPROFEN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL IBUPROFEN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL IBUPROFEN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NAPROXEN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NAPROXEN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NAPROXEN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL TRIPTANS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL TRIPTANS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL TRIPTANS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ALMOTRIPTAN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ALMOTRIPTAN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ALMOTRIPTAN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ELETRIPTAN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ELETRIPTAN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ELETRIPTAN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL FROVATRIPTAN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL FROVATRIPTAN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL FROVATRIPTAN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL NARATRIPTAN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NARATRIPTAN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NARATRIPTAN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL RIZATRIPTAN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL RIZATRIPTAN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL RIZATRIPTAN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL SUMATRIPTAN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL SUMATRIPTAN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL SUMATRIPTAN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ZOLMITRIPTAN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ZOLMITRIPTAN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ZOLMITRIPTAN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TYPES, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL NASAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL NASAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL NASAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CAPSULE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CAPSULE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL TABLET MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL TABLET MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL TABLET MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL TOPICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL TOPICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL TOPICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ACUTE TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ACUTE TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ACUTE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL PREVENTIVE TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL PREVENTIVE TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL PREVENTIVE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL ADULT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL ADULT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL SPECIALTY CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL SPECIALTY CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL SPECIALTY CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL ONLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY NSAID, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY TYPES, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE, BY NSAID, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE, BY TYPES, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA MIGRAINE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA MIGRAINE DRUGS MARKET SIZE, BY NSAID, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA MIGRAINE DRUGS MARKET SIZE, BY TYPES, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA MIGRAINE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE MIGRAINE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE MIGRAINE DRUGS MARKET SIZE, BY NSAID, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE MIGRAINE DRUGS MARKET SIZE, BY TYPES, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE MIGRAINE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST MIGRAINE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST MIGRAINE DRUGS MARKET SIZE, BY NSAID, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST MIGRAINE DRUGS MARKET SIZE, BY TYPES, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 202. MIDDLE EAST MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST MIGRAINE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. MIDDLE EAST MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA MIGRAINE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA MIGRAINE DRUGS MARKET SIZE, BY NSAID, 2018-2032 (USD MILLION)
  • TABLE 211. AFRICA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2032 (USD MILLION)
  • TABLE 212. AFRICA MIGRAINE DRUGS MARKET SIZE, BY TYPES, 2018-2032 (USD MILLION)
  • TABLE 213. AFRICA MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 214. AFRICA MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 215. AFRICA MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 216. AFRICA MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 217. AFRICA MIGRAINE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. AFRICA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 219. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 220. ASEAN MIGRAINE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 221. ASEAN MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN MIGRAINE DRUGS MARKET SIZE, BY NSAID, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN MIGRAINE DRUGS MARKET SIZE, BY TYPES, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 230. ASEAN MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN MIGRAINE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 233. ASEAN MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 234. GCC MIGRAINE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 235. GCC MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 236. GCC MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 237. GCC MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 238. GCC MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2032 (USD MILLION)
  • TABLE 239. GCC MIGRAINE DRUGS MARKET SIZE, BY NSAID, 2018-2032 (USD MILLION)
  • TABLE 240. GCC MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2032 (USD MILLION)
  • TABLE 241. GCC MIGRAINE DRUGS MARKET SIZE, BY TYPES, 2018-2032 (USD MILLION)
  • TABLE 242. GCC MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 243. GCC MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 244. GCC MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 245. GCC MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 246. GCC MIGRAINE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 247. GCC MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPEAN UNION MIGRAINE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPEAN UNION MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPEAN UNION MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION MIGRAINE DRUGS MARKET SIZE, BY NSAID, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPEAN UNION MIGRAINE DRUGS MARKET SIZE, BY TYPES, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPEAN UNION MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPEAN UNION MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPEAN UNION MIGRAINE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 262. BRICS MIGRAINE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 263. BRICS MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 264. BRICS MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 265. BRICS MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 266. BRICS MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2032 (USD MILLION)
  • TABLE 267. BRICS MIGRAINE DRUGS MARKET SIZE, BY NSAID, 2018-2032 (USD MILLION)
  • TABLE 268. BRICS MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2032 (USD MILLION)
  • TABLE 269. BRICS MIGRAINE DRUGS MARKET SIZE, BY TYPES, 2018-2032 (USD MILLION)
  • TABLE 270. BRICS MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 271. BRICS MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 272. BRICS MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 273. BRICS MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 274. BRICS MIGRAINE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 275. BRICS MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 276. G7 MIGRAINE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 277. G7 MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 278. G7 MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 279. G7 MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 280. G7 MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2032 (USD MILLION)
  • TABLE 281. G7 MIGRAINE DRUGS MARKET SIZE, BY NSAID, 2018-2032 (USD MILLION)
  • TABLE 282. G7 MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2032 (USD MILLION)
  • TABLE 283. G7 MIGRAINE DRUGS MARKET SIZE, BY TYPES, 2018-2032 (USD MILLION)
  • TABLE 284. G7 MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 285. G7 MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 286. G7 MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 287. G7 MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 288. G7 MIGRAINE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 289. G7 MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 290. NATO MIGRAINE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 291. NATO MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 292. NATO MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 293. NATO MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 294. NATO MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2032 (USD MILLION)
  • TABLE 295. NATO MIGRAINE DRUGS MARKET SIZE, BY NSAID, 2018-2032 (USD MILLION)
  • TABLE 296. NATO MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2032 (USD MILLION)
  • TABLE 297. NATO MIGRAINE DRUGS MARKET SIZE, BY TYPES, 2018-2032 (USD MILLION)
  • TABLE 298. NATO MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 299. NATO MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 300. NATO MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 301. NATO MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 302. NATO MIGRAINE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 303. NATO MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 304. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 305. UNITED STATES MIGRAINE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 306. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 307. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 308. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 309. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2032 (USD MILLION)
  • TABLE 310. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY NSAID, 2018-2032 (USD MILLION)
  • TABLE 311. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2032 (USD MILLION)
  • TABLE 312. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY TYPES, 2018-2032 (USD MILLION)
  • TABLE 313. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 314. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 315. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 316. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 317. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 318. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 319. CANADA MIGRAINE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 320. CANADA MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 321. CANADA MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 322. CANADA MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 323. CANADA MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2032 (USD MILLION)
  • TABLE 324. CANADA MIGRAINE DRUGS MARKET SIZE, BY NSAID, 2018-2032 (USD MILLION)
  • TABLE 325. CANADA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2032 (USD MILLION)
  • TABLE 326. CANADA MIGRAINE DRUGS MARKET SIZE, BY TYPES, 2018-2032 (USD MILLION)
  • TABLE 327. CANADA MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 328. CANADA MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 329. CANADA MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 330. CANADA MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 331. CANADA MIGRAINE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 332. CANADA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 333. MEXICO MIGRAINE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 334. MEXICO MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 335. MEXICO MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 336. MEXICO MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 337. MEXICO MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2032 (USD MILLION)
  • TABLE 338. MEXICO MIGRAINE DRUGS MARKET SIZE, BY NSAID, 2018-2032 (USD MILLION)
  • TABLE 339. MEXICO MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2032 (USD MILLION)
  • TABLE 340. MEXICO MIGRAINE DRUGS MARKET SIZE, BY TYPES, 2018-2032 (USD MILLION)
  • TABLE 341. MEXICO MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 342. MEXICO MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 343. MEXICO MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 344. MEXICO MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 345. MEXICO MIGRAINE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 346. MEXICO MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 347. BRAZIL MIGRAINE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 348. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 349. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 350. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 351. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2032 (USD MILLION)
  • TABLE 352. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY NSAID, 2018-2032 (USD MILLION)
  • TABLE 353. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2032 (USD MILLION)
  • TABLE 354. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY TYPES, 2018-2032 (USD MILLION)
  • TABLE 355. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 356. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 357. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 358. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 359. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 360. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 361. UNITED KINGDOM MIGRAINE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 362. UNITED KINGDOM MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 363. UNITED KINGDOM MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 364. UNITED KINGDOM MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 365. UNITED KINGDOM MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2032 (USD MILLION)
  • TABLE 366. UNITED KINGDOM MIGRAINE DRUGS MARKET SIZE, BY NSAID, 2018-2032 (USD MILLION)
  • TABLE 367. UNITED KINGDOM MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2032 (USD MILLION)
  • TABLE 368. UNITED KINGDOM MIGRAINE DRUGS MARKET SIZE, BY TYPES, 2018-2032 (USD MILLION)
  • TABLE 369. UNITED KINGDOM MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 370. UNITED KINGDOM MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 371. UNITED KINGDOM MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 372. UNITED KINGDOM MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 373. UNITED KINGDOM MIGRAINE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 374. UNITED KINGDOM MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 375. GERMANY MIGRAINE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 376. GERMANY MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 377. GERMANY MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 378. GERMANY MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 379. GERMANY MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2032 (USD MILLION)
  • TABLE 380. GERMANY MIGRAINE DRUGS MARKET SIZE, BY NSAID, 2018-2032 (USD MILLION)
  • TABLE 381. GERMANY MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2032 (USD MILLION)
  • TABLE 382. GERMANY MIGRAINE DRUGS MARKET SIZE, BY TYPES, 2018-2032 (USD MILLION)
  • TABLE 383. GERMANY MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 384. GERMANY MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 385. GERMANY MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 386. GERMANY MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 387. GERMANY MIGRAINE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 388. GERMANY MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 389. FRANCE MIGRAINE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 390. FRANCE MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 391. FRANCE MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)

T